

Press release from Emotra AB (publ)

Göteborg, February 24, 2020

EMOTRA AB: Resolution on a new rights issue of shares for continued documentation and future market introduction of EDOR® - Corrected (Correction: This correction regards a mistake in the terms for subscription warrants; the correct terms are stated below under "Summary of terms for subscription warrants")

Today, February 24, 2020, EMOTRA AB ("Emotra" or the "Company") announced that the Board has decided to carry out a rights issue comprising a maximum of 8,796,586 units. Each unit comprises two (2) shares and two (2) subscription warrants. If fully subscribed, this rights issue will provide Emotra with a cash injection of appr. 7 MSEK before issue expenses. The Company has already received written commitments for approximately 3.5 MSEK, or about 50 per cent of the issue amount. This rights issue resolution was decided based on the mandate that the Board was granted at the Annual General Meeting on May 15, 2019. The object of this rights issue is to strengthen the Company's working capital for continued clinical documentation and the future market launch of its EDOR® method.

Daniel Poté, our CEO, says:

"After we shifted the focus of our strategy at the beginning of 2018 to psychiatric hospitals and hospital chains in a few of Europe's largest metropolitan areas, we gained a lot of valuable insights. We have understood that the clinical results from a study of the connection between hyporeactivity and the risk of depression relapse attracts a lot of interest. If further clinical studies confirm these previous observations, we see a strong market potential for EDOR®. A series of blind clinical studies, plus a recent study that was based on a compilation of the results from our previous studies, has provided clinical evidence that hyporeactivity is a strong, biologically based risk factor. So far, hyporeactivity is the only clear biomarker that has been demonstrated and it provides an excellent complement to the psychologically and socially conditioned risk factors that can be examined through traditional clinical interviews.

In order to reap the full market potential and commercial opportunities of the EDOR® method, we plan on raising a maximum of 7 MSEK through a new share issue with right of priority. These new funds will allow us to persevere with our strategy and carry out clinical studies in order to confirm our previously reported results on depression relapse."

Rights issue to continue our market introduction of EDOR®

Emotra intends to carry out a rights issue comprising Units amounting to approximately 7 MSEK where each unit comprises two (2) shares and two (2) subscription warrants. The funds from this rights issue is primarily intended to finance our continued clinical documentation and future marketing efforts. Emotra also intends to dedicate some of the funds to continued development of our product's hardware and software, as well as to continued research in order to secure the Company's position at the forefront of this area.

The offering in summary

- **Subscription period:** March 4 to March 18, 2020
- **Subscription price:** 0.80 SEK per Unit, corresponding to 0.40 SEK per share.
- **Record day:** March 2, 2020. The final day for trading in the shares, including the right to obtain unit rights, is February 27, 2020, and the first day without obtaining subscription rights is February 28, 2020.
- **Preferential right:** Shareholders whose Emotra shares are registered on March 2, 2020 will have right of priority to subscribe for units in the new share issue. Each outstanding share

entitles the owner to one (1) unit right. Three (3) unit rights entitles the owner to subscribe for one (1) unit. Please note that this new share issue is also open to the general public.

- **Issue volume:** The offering comprises a maximum of 8,796,586 units. If fully subscribed, the new share issue will provide the Company with appr. 7.04 MSEK before issue expenses.
- **Number of shares outstanding before the new issue:** 26,389,759.
- **Change in number of shares and share capital evolution:** In a first step, this rights issue, if fully subscribed, will increase the Company's share capital by 334,270.27 SEK, from 501,405.42 SEK to 835,675.69 SEK, as well as increase the number of outstanding shares by a maximum of 17,593,172 shares, from 26,389,759 shares to 43,982,931 shares. If fully utilised, the subscription warrants will increase the share capital by a further 334,270.27 SEK, to a total of 1,169,945.95 SEK, and increase the total number of outstanding shares by 17,593,172 shares to 61,576,103 shares.
- **Trading in unit rights:** Trading in unit rights will be carried out on Spotlight Stock Market from March 4, 2020 to March 16, 2020.
- **Trading in PSUs:** Trading in PSUs (Paid Subscribed Units) will be carried out on Spotlight Stock Market from March 4, 2020, until the new issue has been registered at Bolagsverket (The Swedish Companies Registration Office). This registration is planned to take place at the end of March, 2020.
- **Guarantee commitments:** Emotra has received guarantee commitments for about 3.5 MSEK, which equals approximately 50% of the total issue volume.
- **Market place:** Emotra's share is listed on Spotlight Stock Market.
- **ISIN code:** SE0006851507

Summary of terms for subscription warrants

Subscription price: Each subscription warrant grants its owner the right to subscribe for one (1) new share in the Company at a minimum price of 0.40 SEK per share and a maximum of 0.80 SEK per share.

Subscription period: Warrant-based share subscriptions will take place during the period October 9 to 23, 2020. The subscription is executed by simultaneously depositing the cash amount due no later than 3 p.m. on Friday, October 23, 2020.

Final trading day: The final trading day for subscription warrants is scheduled for October 21, 2020.

Memorandum (including complete terms and instructions and further information about subscription commitments) as well as a teaser and subscription form without right of priority will be available on the Company's web site (www.emotra.se), Mangold Fondkommission's web site (www.mangold.se) and Spotlight Stock Market's web site (www.spotlightstockmarket.com) no later than the commencement of the subscription period.

Investor meetings

Life Science Day in Göteborg, Sweden, March 4, 2020, Wallenbergsalen at the Sahlgrenska University Hospital's Medicinareberg. Link for registration: <http://www.lifesciencedagen.se/anmaumllan.html>
Mangold Insight Investor day in Stockholm, March 5, 2020, The Scandic Anglais, Humlegården 23, Stockholm, Sweden. Register at: investerarlag@mangold.se

Investor meeting Malmö, Sweden, March 10, 2020, at Mangold's Malmö branch office.

Send your registration to the following address: emissionstjanster@mangold.se

Emission Institute

Emotra's project leader in connection with the planned rights issue is Mangold Fondkommission.

For further information about the planned rights issue, please contact:

Mangold Fondkommission AB
Telephone: +46 8 503 01 551
E-mail: emissioner@mangold.se

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 732 34 41 93, E-mail: daniel@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on February 24, 2020, under the above contact's supervision.

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se